Pýrasólam

Pyrazolam is a research chemical depressant of the triazolobenzodiazepine class. Originally developed at Hoffmann-La Roche in the 1970s, it emerged on the research chemical market around 2012. Pyrazolam is distinguished from other benzodiazepines by its predominantly anxiolytic profile, producing comparatively less sedation and euphoria at common doses. It is structurally related to alprazolam and bromazepam and is notably reported to pass through the body unmetabolized.

Also known as: Sh-i-04, Pirazolam

Classification

Chemical: Benzodiazepine
Psychoactive: Depressant
Tag: Anxiolytic
Tag: GABAergic
Tag: Habit-Forming
Tag: Muscle Relaxant
Tag: Research-Chemical

Effects

Sedation
Muscle Relaxation
Respiratory Depression
Anxiolytic
Sedative
Dystaxia
Amnesia
Anxiety Suppression
Thought Deceleration
Information Processing Suppression
Compulsive Redosing
Delusions Of Sobriety
Disinhibition
Warmth
Dulled Perception

Routes of Administration

Oral

Dosage

Heavy: 3+ mg
Light: 0.5 – 0.75 mg
Common: 0.75 – 1.5 mg
Strong: 1.5 – 3 mg
Threshold: 0.25 mg

Duration

Onset: 0.17-0.25 h
After Effects: 1-12 h
Peak: 1-3 h
Offset: 4-6 h
Total Duration: 4-8 h

Insufflated

Dosage

No data available for this section yet.

Duration

Onset: 0.08 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu